AL3818 not checked

Advenchen Laboratories, LLC

FollowEvery change as it happens, and a Monday email
Stage
in China
Next date
Phase 3 trial completes
Trials
3 active
5 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Anlotinib (AL3818) 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)”In the company’s words, NCT03016819 on ClinicalTrials.gov
Tested for
Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma, Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma
Main trialPhase 3
“THIS STUDY IS CURRENTLY RECRUITING PATIENTS WITH ALVEOLAR SOFT PART SARCOMA ONLY AND IS NO LONGER RECRUITING PATIENTS WITH SYNOVIAL SARCOMA OR LEIOMYOSARCOMA. This study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride in the treatment of metastatic or advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), and synovial sarcoma (SS). All participants with ASPS will receive open-label AL3818. In participants with LMS or SS, AL3818 will be compared to IV dacarbazine. Two-thirds of the participants will receive AL3818, one-third of the participants will receive IV…”In the company’s words, NCT03016819 on ClinicalTrials.gov
Other names
Anlotinib Hydrochloride · Anlotinib · Catequentinib · Catequentenib

Other drugs for Alveolar Soft Part Sarcoma

All 7 drugs for Alveolar Soft Part Sarcoma

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Dec 2027 Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
Phase 1/2Not yet recruiting 1 Sep 2030 A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers
Phase 1Not yet recruiting 31 Mar 2027 Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers
Phase 3Unknown Oct 2024 Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
Phase 3Ended not given A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects with Recurrent or Metastatic Endometrial,Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow AL3818

Following is part of Solo: you see every change to AL3818 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in